Core Insights - Ocular Therapeutix, Inc. is actively participating in several investor conferences in May 2025, showcasing its commitment to engaging with the investment community [1][2][3]. Conference Participation - The company will present at the 2025 RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat scheduled for 2:35 PM ET [2]. - Ocular will also participate in the HC Wainwright 3 Annual BioConnect Investor Conference on the same day, with another fireside chat at 4:30 PM ET [2]. - Additionally, Ocular will host investor one-on-one meetings at the Mizuho Neuro & Ophthalmology Summit on May 21, 2025, and will participate in the Stifel Virtual Ophthalmology Forum on May 27, 2025, with a fireside chat at 3:00 PM ET [3]. Product Pipeline - Ocular Therapeutix is focused on redefining the retina experience with its investigational product AXPAXLI™ (OTX-TKI), which is currently in Phase 3 clinical trials for wet age-related macular degeneration [4]. - The company also leverages its proprietary ELUTYX™ technology in its commercial product DEXTENZA, an FDA-approved corticosteroid for treating ocular inflammation and pain, as well as in its investigational product PAXTRAVA™ (OTX-TIC), which is in Phase 2 clinical trials for open-angle glaucoma or ocular hypertension [5].

Company Participation in Investor Conferences - Ocular Therapeutix, Inc. will participate in the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 3:00 PM ET, with Dr. Pravin U. Dugel presenting [1] - The company will also host investor one-on-one meetings at the Piper Sandler Spring Biopharma Symposium on April 17, 2025, in Boston, MA [2] Product Pipeline and Technology - Ocular Therapeutix is focused on redefining the retina experience, with its product candidate AXPAXLI™ (axitinib intravitreal hydrogel) currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) [3] - The company utilizes its proprietary ELUTYX™ bioresorbable hydrogel-based formulation technology in its commercial product DEXTENZA®, which is FDA-approved for treating ocular inflammation and pain following surgery, as well as in PAXTRAVA™ (travoprost intracameral hydrogel), currently in Phase 2 clinical trials for open-angle glaucoma or ocular hypertension [4]